|
|
News Breaks | | | | February 25, 2013 | | 07:02 EDT |  | DYAX | Dyax presents DX-2930 data at AAAAI Annual Meeting
Dyax announced results from a preclinical study of DX-2930, their internally developed, fully human monoclonal antibody inhibitor of plasma kallikrein, at the 2013 American Academy of Allergy, Asthma and Immunology Annual Meeting which is taking place February 22-26 in San Antonio, TX. The poster, titled “Discovery and characterization of a fully human monoclonal antibody inhibitor of plasma kallikrein for the treatment of plasma kallikrein-mediated edema,” highlighted results of preclinical work that was designed to evaluate the activity of DX-2930 as a long-acting inhibitor of plasma kallikrein. Dyax currently markets KALBITOR, a specific pKal inhibitor, for treatment of acute hereditary angioedema attacks in patients 16 years of age and older. The company is exploring DX-2930 as a subcutaneous, long-acting, prophylactic treatment for HAE. Based upon the attributes of selectivity, specificity and long half-life Dyax has chosen to develop DX-2930 as a self-administered, subcutaneous injection for chronic prevention of HAE attacks. The company plans to file an Investigational New Drug application with the FDA by the end of the second quarter of 2013 and expects to initiate Phase 1 clinical studies in the second half of 2013. Data demonstrate that DX-2930 is a potent antibody inhibitor of pKal (Ki=0.14 nM) that does not bind prekallikrein or any other serine protease tested. In a preclinical model, DX-2930 reduced carrageenan-induced edema. Pharmacokinetic properties following subcutaneous injection indicate that the antibody is bioavailable (66%) and has a half-life of 12.5 days in non-human primates. | |
|
News For DYAX From The Last 14 Days Check below for free stories on DYAX the last two weeks. |
|
|
| May 13, 2013 | | 07:16 EDT |  | DYAX | Dyax raises $30M in a registered direct offering
 Subscribe for More Information | |
|
|
|
|
|
|
